OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Update on MRD Testing in Acute Lymphoblastic Leukemia

home / peer-exchange / mrd-testing-in-all
Prognostic Factors in Acute Lymphoblastic Leukemia

EP. 1: Prognostic Factors in Acute Lymphoblastic Leukemia

February 1st 2020
Considering Induction Regimens for ALL

EP. 2: Considering Induction Regimens for ALL

February 1st 2020
Induction Strategies for Philadelphia-Positive ALL

EP. 3: Induction Strategies for Philadelphia-Positive ALL

February 1st 2020
ALL: Cytogenetics and T-Cell Versus B-Cell Induction Strategies

EP. 4: ALL: Cytogenetics and T-Cell Versus B-Cell Induction Strategies

February 1st 2020
Acute Lymphoblastic Leukemia: Optimal Timing of HSCT

EP. 5: Acute Lymphoblastic Leukemia: Optimal Timing of HSCT

February 1st 2020
MRD in ALL: Prognostic Importance and Multidisciplinary Care

EP. 6: MRD in ALL: Prognostic Importance and Multidisciplinary Care

February 1st 2020
ALL: When and Who to Test for Minimal Residual Disease

EP. 7: ALL: When and Who to Test for Minimal Residual Disease

February 1st 2020
Strategies to Assess Minimal Residual Disease

EP. 8: Strategies to Assess Minimal Residual Disease

February 1st 2020
Sensitivity of MRD Testing and Impact on Decisionmaking in ALL

EP. 9: Sensitivity of MRD Testing and Impact on Decisionmaking in ALL

February 1st 2020
MRD's Impact on Subsequent Therapy Choice in ALL

EP. 10: MRD's Impact on Subsequent Therapy Choice in ALL

February 1st 2020
MRD+ ALL: Evolving Role of BiTE Therapy

EP. 11: MRD+ ALL: Evolving Role of BiTE Therapy

February 1st 2020
Optimizing Use of Maintenance Therapy in ALL

EP. 12: Optimizing Use of Maintenance Therapy in ALL

February 1st 2020
Future Directions for MRD Testing in ALL

EP. 13: Future Directions for MRD Testing in ALL

February 1st 2020
MRD Testing in Hematologic Malignancies Other Than ALL

EP. 14: MRD Testing in Hematologic Malignancies Other Than ALL

February 1st 2020
Acute Lymphoblastic Leukemia: Future Directions in Therapy

EP. 15: Acute Lymphoblastic Leukemia: Future Directions in Therapy

February 1st 2020

Latest Conference Coverage

Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL

Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL

Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL

BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact